scholarly article | Q13442814 |
P2093 | author name string | Lawrence Blonde | |
Zinnia T San Juan | |||
P2860 | cites work | Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. | Q51563377 |
Impact of dosage frequency on patient compliance. | Q53964327 | ||
Patient perspectives on multiple medications versus combined pills: a qualitative study | Q56783264 | ||
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 | ||
Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study | Q28214017 | ||
Clinical outcomes and adherence to medications measured by claims data in patients with diabetes | Q30977056 | ||
Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature | Q33436395 | ||
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy | Q34656261 | ||
Fixed-dose combinations improve medication compliance: a meta-analysis. | Q34659858 | ||
Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components | Q34774198 | ||
Approaches to patient education: emphasizing the long-term value of compliance and persistence | Q36431210 | ||
Impact of fixed-dose combination drugs on adherence to prescription medications | Q36572787 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. | Q37327697 | ||
Differences in psychometric properties, cut-off scores, and outcomes between the Barthel Index and Modified Rankin Scale in pharmacotherapy-based stroke trials: systematic literature review | Q37472147 | ||
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control | Q37621774 | ||
Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice | Q39643925 | ||
The burden of treatment failure in type 2 diabetes | Q40500624 | ||
Fixed-dose combinations of antituberculous medications to prevent drug resistance | Q40528410 | ||
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors | Q42171281 | ||
Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea | Q43108038 | ||
Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. | Q43261599 | ||
Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus | Q43738827 | ||
Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients | Q43938840 | ||
Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy | Q43958331 | ||
Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. | Q44016357 | ||
Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus | Q44354569 | ||
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea | Q44507814 | ||
Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co‐administered with metformin | Q44655649 | ||
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. | Q45974567 | ||
Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure | Q46847942 | ||
Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. | Q51467253 | ||
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. | Q51471806 | ||
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. | Q51488169 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | type 2 diabetes | Q3025883 |
P304 | page(s) | 1-13 | |
P577 | publication date | 2012-01-16 | |
P1433 | published in | Advances in Therapy | Q4686392 |
P1476 | title | Fixed-dose combinations for treatment of type 2 diabetes mellitus | |
P478 | volume | 29 |
Q38858795 | A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA from 2007-2013 |
Q35102138 | A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy |
Q38223104 | Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes |
Q34824247 | Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes |
Q52657004 | Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force. |
Q38603506 | Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes |
Q89461801 | Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial |
Q38577303 | Empagliflozin/Linagliptin: A Review in Type 2 Diabetes |
Q48140061 | Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach |
Q53097629 | Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial. |
Q38387034 | Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia |
Q26766404 | Patient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XR |
Q39170345 | Pharmacotherapy of 'treatment resistant' type 2 diabetes |
Q35428960 | Pill Burden in Patients With Type 2 Diabetes in Germany: Subanalysis From the Prospective, Noninterventional PROVIL Study |
Q84554797 | Recent publications by ochsner authors |
Q55041856 | Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ). |
Q28069065 | Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease |
Q38920983 | The power of two: an update on fixed-dose combinations for type 2 diabetes |
Q47716792 | Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment. |
Q35674552 | Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study |
Q30240030 | Understanding and overcoming metformin gastrointestinal intolerance. |
Q51246605 | Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification. |